A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma

被引：0

作者：

Salles, Gilles ^{[1
]}

Shah, Harsh ^{[2
]}

Leonard, John P. ^{[3
]}

Szanto, Attila ^{[4
]}

Chen, Jade ^{[4
]}

Bannerji, Rajat ^{[4
]}

Morschhauser, Franck ^{[5
]}

Nastoupil, Loretta J. ^{[6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Utah, Salt Lake City, UT USA

[3] Weill Cornell Med, New York, NY USA

[4] Epizyme, Cambridge, MA USA

[5] Univ Lille, CHU Lille, ULR 7365, GRITA,Grp Rech Formes Injectables & Technol Assoc, Lille, France

[6] UT MD Anderson Canc Ctr, Houston, TX USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; follicular lymphoma; non-Hodgkin lymphoma; enhancer of zeste homolog 2 protein; epigenetics; tazemetostat; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-485

引用

页码：S454 / S455

页数：2

共 50 条

[1] A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
Leonard, John
Batlevi, Connie Lee
Gabrail, Nashat
Pagel, John M.
Yang, Jay
Whalen, Jennifer
Adib, Deyaa
Morschhauser, Franck
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S279 - S279
[2] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Leonard, John P.
Trneny, Marek
Izutsu, Koji
Fowler, Nathan H.
Hong, Xiaonan
Zhu, Jun
Zhang, Huilai
Offner, Fritz
Scheliga, Adriana
Nowakowski, Grzegorz S.
Pinto, Antonio
Re, Francesca
Fogliatto, Laura Maria
Scheinberg, Phillip
Flinn, Ian W.
Moreira, Claudia
Cabecadas, Jose
Liu, David
Kalambakas, Stacey
Fustier, Pierre
Wu, Chengqing
Gribben, John G.
Calaminici, Maria
Copie-Bergman, Christiane
Lopez-Guillermo, Armando
O'Connor, Owen
Williams, Michael
Suciu, Stefan
Levine, Benjamin
Kern, Julie
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
[3] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Della Cioppa, P.
Lucania, A.
Esposito, M.
Improta, S.
Mastrullo, L.
HAEMATOLOGICA, 2015, 100 : 151 - 151
[4] Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
Batlevi, Connie Lee
Park, Steven I.
Nastoupil, Loretta
Phillips, Tycel
Amengual, Jennifer E.
Andorsky, David
Campbell, Philip
McKay, Pamela
Pagel, John M.
Leonard, John P.
Yang, Jay
O'Connor, Heather
Hamlett, Anthony
Adib, Deyaa
Morschhauser, Franck
BLOOD, 2021, 138
[5] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
Sehn, Laurie Helen
Hubel, Kai
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe Marc
Paneesha, Shankara
Trneny, Marek
Mashegu, Hafsat Umar
Lihou, Christine Francis
Li, Di
Scholz, Christian W.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Gribben, J.
Trneny, M.
Izutsu, K.
Fowler, N. H.
Hong, X.
Zhu, J.
Zhang, H.
Offner, F.
Scheliga, A.
Nowakowski, G.
Pinto, A.
Re, F.
Fogliatto, L. M.
Scheinberg, P.
Flinn, I.
Moreira, C.
Liu, D.
Kalambakas, S.
Fustier, P.
Wu, C.
Leonard, J. P.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 79 - 79
[7] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Batlevi, Connie Lee
Park, Steven I.
Phillips, Tycel Jovelle
Amengual, Jennifer
Andorsky, David Jacob
Campbell, Philip
Mckay, Pamela
Leonard, John Paul
Sondhi, Manu
Yang, Jay
Chen, Yingxue
O'Connor, Heather
Slatcher, Pamela
Morschhauser, Franck
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Hou, Jian
Jin, Jie
Xu, Yan
Wu, Depei
Ke, Xiaoyan
Zhou, Daobin
Lu, Jin
Du, Xin
Chen, Xiequn
Li, Junmin
Liu, Jing
Gupta, Neeraj
Hanley, Michael J.
Li, Hongmei
Hua, Zhaowei
Wang, Bingxia
Zhang, Xiaoquan
Wang, Hui
van de Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
[9] Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Jian Hou
Jie Jin
Yan Xu
Depei Wu
Xiaoyan Ke
Daobin Zhou
Jin Lu
Xin Du
Xiequn Chen
Junmin Li
Jing Liu
Neeraj Gupta
Michael J. Hanley
Hongmei Li
Zhaowei Hua
Bingxia Wang
Xiaoquan Zhang
Hui Wang
Helgi van de Velde
Paul G. Richardson
Philippe Moreau
Journal of Hematology & Oncology, 10
[10] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
Sehn, Laurie H.
Hubel, Kai
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe
Paneesha, Shankara
Trneny, Marek
Mashegu, Hafsat
Lihou, Christine F.
Cheng, Lulu
Scholz, Christian W.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386

← 1 2 3 4 5 →